Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | F3 | P13726 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117907 | 0.90 | ALDH1A1 (0.41) | ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL3123596 | 0.86 | MAPT (0.48) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3131098 | 0.85 | L3MBTL1 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3117589 | 0.84 | L3MBTL1 (0.44) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3129614 | 0.83 | PDE4B (0.40) | ALDH1A1LMNAHTT | |
| SCHEMBL3129220 | 0.83 | PDE4A (0.38) | — | |
| SCHEMBL3126180 | 0.81 | AAK1 (0.39) | F7ALDH1A1F3LMNAF10 | |
| SCHEMBL3129484 | 0.75 | F7 (0.43) | F7F3SLC6A2SLC6A4F10 | |
| SCHEMBL3123524 | 0.73 | PDE4D (0.49) | ALDH1A1SLC6A2SLC6A4ALPL | |
| SCHEMBL3123550 | 0.72 | F2 (0.42) | F7ALDH1A1LMNASMN1; SMN2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | F7 3964/4885ALDH1A1 190/4885F3 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.